TP53 and myelodysplastic syndrome: Aezea (Cenersen) (235) is a 20-mer phosphorothioate ASO with a specific nucleotide sequence 5′-d[P-Thio] (CCCTG CTCCC CCCTG GCTCC)- 3′ that acts on TP53, which encodes for the undruggable tumor protein p53.557 Cenersen has entered phase I clinical trials for treatment of myelodysplastic syndromes (NCT02243124) and phase II for lymphoma and acute myelogenous leukemia (NCT00967512, NCT00074737, NCT00636155), either alone or in combination with chemotherapy.